Roche: We’ve Abandoned Budgets And It’s Liberated Employees
Executive Summary
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?
You may also be interested in...
Bucking Biosimilar Threat, Roche Sees Further Growth
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
GSK Revamps Sales Reps Incentives To Be Competitive In Cancer
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.
Investors Take Flight After Bluebird Bio’s Sickle Cell Delay
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.